Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An update from Island Pharmaceuticals Ltd ( (AU:ILA) ) is now available.
Island Pharmaceuticals Ltd announced a US non-deal roadshow where CEO Dr. David Foster will meet with US investors to discuss the clinical pathway for ISLA-101, their lead asset against dengue fever, and potential pipeline expansions. This roadshow aims to attract interest from US investors and provide insights into the company’s development phase, positioning Island Pharmaceuticals for future growth and potential FDA approval benefits.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian drug repurposing company focused on developing antiviral therapeutics to address infectious diseases. The company’s lead asset, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases.
Average Trading Volume: 150,565
Technical Sentiment Signal: Buy
Current Market Cap: A$33.64M
See more data about ILA stock on TipRanks’ Stock Analysis page.